[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 12 sources · 6 days · First seen · Last updated

GSK third quarter 2026 financial performance

Overview

GSK reported third quarter revenue of £8.9 billion, representing a 5% increase at constant exchange rates. This growth was primarily driven by the Specialty Medicines division, which saw a 23% rise in oncology sales and a 10% increase in HIV treatments.

However, the company experienced a 16% decrease in total operating profit, falling to £2.1 billion. This decline was attributed to £328 million in restructuring costs associated with the ‘Accelerate Growth’ program, a three year initiative intended to reallocate resources toward R&D and generate annual savings of £1.9 billion by 2029.

While core operating profit rose by 5% to £3.1 billion, exceeding analyst expectations, the vaccine segment saw a 2% decline in sales. Specific decreases were noted in the shingles vaccine Shingrix and the RSV vaccine Arexvy, partly due to reduced demand in the United States and China.

Entities

GSK · Marsh · Business Group on Health · Hesham Abdullah · Mercer

Timeline

  1. [BUSINESS] 3 sources
    GSK reports 4% revenue growth in third quarter 2026

    GSK reported Q3 2026 revenue of 8.9 billion pounds, a 4% increase driven by Specialty Medicines, despite restructuring costs impacting total operating profit.

  2. [BUSINESS] 9 sources
    GSK reports Q3 revenue growth driven by specialty medicines

    GSK's Q3 revenue rose 5% to £8.9 billion, led by oncology and HIV drugs, despite a decline in vaccine sales and restructuring costs impacting total operating profit.

Sources

ad-hoc-news.de · cashcow.nl · econoTimes.com · empleo.com · farmaciavirtuale.it · finanzen.at · finanzen.ch · fr.businessam.be · medicaldialogues.in · proactiveinvestors.co.uk · teleborsa.it · thebionews.net